Roche ’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
Basel, 27 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patient s with PDS who received refills every six months achieved visual acuity outcomes equivalent to those receiving monthly ranibizumab 0.5 mg injections. In Archway, PDS was generally well-tolerated with a favorable benefit-risk profile. Neovascular AMD is a leading cause of blindness in people aged 60 and older globally. [1,2] The current standard of care for nAMD requires patients to visit their ophthalmologist as often as monthly for eye injections of anti-vascular endothelial growth factor (VEGF) therapy to help maintain vision gains and/or prevent vision loss. [3] This high treatment burden with anti-VEGF therapy can lead to under-treatment of nAMD and, potentially, less than optimal vision outcomes. [3,4]" For people around the world receiving frequent eye injections for neovascular AMD, this continuous delivery system could greatly reduce their treatment burden, ” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product De...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Age-Related Macular Degeneration (AMD) | Allergy & Immunology | Biotechnology | Bleeding | Blindness | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Endocrinology | Epidemiology | European Medicines Agency (EMA) | Eyes | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Heart | Infectious Diseases | International Medicine & Public Health | Internet | Japan Health | Lucentis | Managed Care | Men | Opthalmology | Pharmaceuticals | Ranibizumab Injection | Science | Study | Switzerland Health | UK Health | USA Health | Vitamin A | WHO